Research

DRIVE PK Trial –  AG-348

Pyruvate Kinase deficiency is a manageable disease; however, there are currently no approved medicines that treat the underlying cause of the disorder. At this time Agios Pharmaceuticals has launched its DRIVE PK Trial. This is a phase 2 clinical trial for for the oral medication, AG-348,  This therapy has been developed as a potential treatment for Pyruvate Kinase (PK) deficiency.  Due to a deficiency in the enzyme, pyruvate kinase, people with pk deficiency are anemic, which means they have a reduced number of healthy red blood cells.  The study is being conducted to determine whether AG-348 increases the levels of healthy red blood cells in the body. Trial locations are open at several sites across the USA, as well as in Canada, Italy, and the UK. To learn more about this study visit Agios’  Drive PK Trial website.

* Important to note – There is NO placebo controlled group in this study.

For updated information on pyruvate kinase deficiency clinical studies, go to http://www.clinicaltrials.gov or click on this link: A Study of AG-348 in Adult Patients with PK Deficiency

Watch this video to learn more about what a clinical trial is and how it works. 

Part of the Roche Drawn to Science video Series


Natural History Study

The purpose of this study is to describe the symptoms, treatments, and complications related to Pyruvate Kinase deficiency (PKD). Patients of all ages are eligible to enroll in the study.  Participants will be asked to fill in questionnaires regarding their quality of life. In addition, the study team will collect past medical history and routine clinical care information. Those who are interested in participating or want more information about this study can contact the following researchers:

U.S.A.
Dr. Rachael Grace
Boston Children’s Hospital
Phone: (617) 919-2144
Email: rachael.grace@childrens.harvard.edu

You may go to the following link to get more information about this study:
Pyruvate Kinase Deficiency Natural History Study(PKD NHS)

Europe

Dr. Eduard J van Beers
Van  Creveldkliniek
University Medical Centre
Utrecht, the Netherlands
T: +31 88 75 584 50
F: +31 88 75 554 38


ForGeTPKD – gene therapy

Apart from the activities conducted by Agios Pharmaceuticals to develop a drug treatment for PKD, alternative strategies are also being explored in the field. One of these alternative ways is gene therapy. Gene therapy basically involves correction of the defect at the genetic level in the right cells (hematopoietic stem cells). This has the potential of curing the patient with a hematological disorder, such as PKD. This sounds simple, but in fact it is technically challenging. Nevertheless, a lot of progress has been made over the years for a number of hematological diseases such as sickle cell anemia and thalassemia.
Dr. José Carlos Segovia is a Spanish investigator who has focused his research on developing methods to cure PKD by gene therapy. His approach recently received the Orphan Drug designation for the treatment of PKD by the European Community (EU/3/14/1130). This means that his approach is ready for clinical trial. Together with Dr. Segovia and many other European clinicians and researchers in the field of PKD they have formed a EU consortium.

Dr. José Carlos Segovia
Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT)
Avda. Complutense 22 28040 Madrid • Spain